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Abstract Presenilins (PS1 and PS2) are supposed to be unusu-
al aspartic proteases and components of the Q-secretase complex
regulating cleavage of type I proteins. Multiple mutations in
PS1 are a major cause of familial early-onset Alzheimer’s dis-
ease (AD). We and others recently identi¢ed PS-related families
of proteins (IMPAS/PSH/signal peptide peptidases (SPP)). The
functions of these proteins are yet to be determined. We found
that intramembrane protease-associated or intramembrane pro-
tease aspartic protein Impas 1 (IMP1)/SPP induces intramem-
branous cleavage of PS1 holoprotein in cultured cells coexpress-
ing these proteins. Mutations in evolutionary invariant sites in
hIMP1 or speci¢c Q-secretase inhibitors abolish the hIMP1-
mediated endoproteolysis of PS1. In contrast, neither AD-like
mutations in hIMP1 nor in PS1 substrate abridge the PS1
cleavage. The data suggest that IMP1 is a bi-aspartic polytopic
protease capable of cleaving transmembrane precursor proteins.
These data, to our knowledge, are a ¢rst observation that a
multipass transmembrane protein or the integral protease per
se may be a primary substrate for an intramembranous proteol-
ysis.
- 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The presenilin proteins (PS1 and PS2) are implicated as
critical bi-aspartic proteases for intramembranous processing
of the L-amyloid precursor protein (L-APP), Notch1^4 recep-
tors and several other type I integral proteins [1^3]. PS1 and
PS2 mediate cleavage within single transmembrane domains
of these proteins [1^8]. The primary extracytosolic cleavage of
the substrates by other endoproteases is a prerequisite for the
sequential intramembranous proteolysis regulated by PSs.
Analogous two-step proteolytic mechanisms have recently
been described for some other membrane-associated putative
proteases and their substrates in prokaryotes and eukaryotes.
This process designated as regulated intramembrane proteol-
ysis (RIP) is an important mechanism for inter- and intra-
cellular signaling [1,2]. Missense mutations in PS1 and PS2
and their putative L-APP substrates are a common cause of
familial early-onset Alzheimer’s disease (AD) [9^12]. Most if
not all of these mutations in PSs increase the production of 42
amino acid AL-peptides via the O-/Q-cleavage of APP, but
presumably have no enhancing e¡ect on intramembranous
proteolysis of Notch1 [13,14]. The alternative non-enzymatic
functions of PS proteins in tra⁄cking of cellular proteins or as
cofactors of putative intramembrane proteases have not yet
been ruled out [3]. We and others found recently multiple
families of proteins (termed IMPAS (family of intramembrane
protease-associated or intramembrane protease aspartic pro-
teins (IMPs)) or PSH, signal peptide peptidases (SPP)/SPPL)
related to PSs by homology in several transmembrane do-
mains [15^18]. The function of the di¡erent IMP proteins is
still unknown. One of the proteins, IMP1/SPP, encoded by a
gene located on human chromosome (chr) 20, may cleave
short hydrophobic N-terminal signal peptide remnants, as ini-
tially demonstrated by in vitro translation experiments and by
direct binding of this polytopic protein to (Z-LL)2-ketone in-
hibitor of signal peptide proteolysis [18,19]. We found that the
activity of IMP1/SPP is beyond the cleavage of the signal
peptides. We have identi¢ed a previously unknown type of
intramembrane proteolysis, an endoproteolytic activity of hu-
man IMP1 (hIMP1) against multipass PS1 holoprotein.
2. Materials and methods
2.1. cDNA constructs and antibodies (Abs)
The hIMP1 gene was isolated and cloned as we described (Gen-
Bank accession numbers AY169310, AY169311, AY169312) [15,16].
The PS1 full-length sequence was cloned by reverse transcriptase-poly-
merase chain reaction (RT-PCR) from human leukocyte and brain
cDNA. The hIMP1 C-terminus was fused to V5- or c-myc targets
by subcloning of full-length IMP1 into pcDNA6/V5-His A and
pcDNA4/myc-His B vectors (Invitrogen). A series of missense muta-
tions in hIMP1 gene and stop and missense mutations in PS1 gene
were introduced by PCR with mismatch primer oligonucleotides di-
rectly or by using the quick-change Stratagene kit. Additional trun-
cated PS1 432 st, PS1 441 st constructs with stop codons at the 433
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and 442 residue positions, omitting also spliced VRSQ residues, were
initially obtained from Dr. A. Goate’s laboratory. For the experi-
ments described here, these PS1 isoforms were subcloned into the
wild type of PS1 (PS1wt) harboring VRSQ. The deletion in the 5P-en-
coding region of the PS1 gene was introduced using PCR with a 5P-
oligonucleotide primer missing the internal sequence. The resulting gene
construct (PS1 5P-del) encoded a protein lacking a segment of 23 amino
acids (v5^27 amino acids) following the ¢rst MTEL residues in PS1.
Polyclonal IMP1-N Abs were raised against the hIMP1 N-terminus as
we described [16]. Abs against V5 and c-myc epitopes were obtained
from Invitrogen and Sigma. Sensitive polyclonal rabbit Abs (PS1 N-M)
were raised against hPS1 N-terminal polypeptide (1^93 amino acids).
The 9N14Abs against the ¢rst 1^14 amino acids in N-terminal PS1 were
kindly provided by Dr. A. Goate and PS1 G1L3 Abs against PS1 car-
boxy-terminal fragment (CTF) (epitope between hydrophobic domains
(HDs) VII and VIII) were previously described [20].
2.2. Transfection and Western/immunoblot detection
Human embryonic kidney (HEK)293 or Chinese hamster ovary
(CHO) cells were transiently cotransfected with hIMP1 and PS1 con-
structs or mock plasmids using LipofectAMINE PLUS reagent (In-
vitrogen). Cells lysates or membrane fractions were prepared in 24 h
after transfection. Proteins were electrophoresed in polyacrylamide
gels. To resolve small molecular mass di¡erences between C-termi-
nally truncated 40^45 kDa PS1 isoforms the protein extracts were
loaded onto sodium dodecyl sulfate (SDS)^polyacrylamide gels, and
electrophoresis was run until the 36 kDa marker fragment almost
reached the bottom of the gel. In all ¢gures presented, Tris^glycine
SDS^polyacrylamide gels were used, except in Fig. 2e where tricine^
polyacrylamide gel was used to detect CTF. The PS1 and hIMP1
proteins were detected by immunoblots with the Abs described above
using standard procedures [16]. Whenever indicated, autographs were
scanned and images were analyzed using Quantity One Version 4.3.0
quanti¢cation software (Bio-Rad).
2.3. Intramembrane protease inhibitors
The (Z-LL)2-ketone inhibitor, L-685,458, and N-S-phenyl-glycine-t-
butyl ester (DAPT) compounds were purchased from Calbiochem.
Cell lines transfected with PS1 and hIMP1 isoforms or mock plasmids
were incubated in culture cell media containing di¡erent concentra-
tions of the inhibitors for 24 h before lysis procedures. The cell lysates
were analyzed by Western blots as described above.
Fig. 1. Structure of PS and PS-related IMP proteins. a: Multiple alignments of most conservative domains of protein families: eukaryotic PSs
(PSEN1,2, Homo sapiens ; SEL-12, HOP-1, Caenorhabditis elegans ; Ar.-1PS, Arabidopsis thaliana ; Dict.-PS, Dictyostelium discoideum) ; IMPASes
(hIMP1^5, H. sapiens ; Caen.-IMP-1, Caen.-IMP-2, C. elegans C36B1.12, T05E11.5; S. cerv., Saccharomyces cerevisiae ; Ar.-IMP, A. thaliana
AAC34490; Dict. IMP, D. discoideum); related proteins from Archaea (Arch.fulg., Archaeoglobus fulgidus AAB89302; Th.volc., Thermoplasma
volcanium NP_110537; Th.ac., Thermoplasma acidophilum CAC11210); and bacterial type 4 prepilin peptidases (Burk.ps., Burkholderia pseudo-
mallei ; Pseud.aer., Pseudomonas aeruginosa ; Aer.hyd., Aeromonas hydrophila ; Ther.mar., Thermotoga maritime ; Str.coel., Streptomyces coelico-
lor). Shading, amino acid with similarity inside protein families v 50% (for Archaea v 30%) common for: (1) all protein families are shown in
red; (2) PSs and any other protein family are shown in blue; (3) IMPs and Archaea or bacteria proteins are shown in yellow; (4) Archaea and
bacteria proteins are shown in gray. Amino acid with similarity v 50% only inside any of the protein families are underlined. Beneath amino
acids identical in all members of the IMPAS/PS suprafamily or bacterial peptidases are depicted. Groups of similar amino acids: 1-D,N;
2-E,Q; 3-S,T; 4-K,R; 5-F,Y,W; 6-L,I,V,M (Blosum 62 scoring matrix). Red arrows denote AD-associated amino acid substitutions in con-
servative sites of PS and IMP proteins. Black arrows indicate mutations in IMP1 and PS1 used in this work or catalytically critical aspartic
residues in PS1. b,c: Predicted membrane topology of HD of human PS1 (hPS1) and hIMP1 proteins. b: PS1 topology. HD X is shown in
possible structure conformations as membrane-associated or membrane-spanning domain. White arrowheads denote conservative aspartate (D)
residues and PAL motif. The PAL motives in HD VII and X are shown in bold. Gray arrowheads indicate the sites for ‘PSase’-dependent clea-
vages in HD VII [21]. The predicted cleavage (291^293) and similar motif in HD X are in parentheses. Black arrowheads indicates hIMP1-de-
pendent Z1-cleavage of PS1wt. Sequences of HD are underlined and mutations in HD X used in this work are denoted. c: hIMP1 topology.
White arrowheads denote conservative aspartates (D) and PAL motif. The predicted glycosylation (asterisks) and endoplasmic reticulum (ER)
membrane retention signals are shown.
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3. Results
First, we determined the common sites conserved through-
out evolution of the suprafamily of PSs and PS-related pro-
teins (IMPAS). Comprehensive alignment was developed (Fig.
1a) demonstrating that IMP and PS proteins share the most
identities in three conserved HDs corresponding to PS1 HD
VI, HD VIII and HD IX/HD X. A signi¢cant homology
between IMPAS/PS families and the bacterial type 4 prepilin
peptidases was found in these domains. The data suggested
that PSs (found in a primary form in Protista [16]) and IMP
(found in yeast) might originate from an ancient prototype
eventually evolved into diverged subfamilies of related pro-
teins. The D-6GxGD-PxL (x, any amino acid; 6, aliphatic
non-polar hydrophobic, e.g. L, I, V or M amino acid) is an
invariant signature of the IMPAS/PS suprafamily and bacte-
rial peptidases (Fig. 1a), which may be critically required for
their proteolytic properties.
The predicted topology and structure of K-helical trans-
membrane domains in hIMP1 and PS1 are similar. In addi-
tion, PSs have a HD (HD VII) cleaved by ‘presenilinase’
(PSase) activity. hIMP1 forms complexes and is glycosylated
Fig. 2. Expression of hIMP1 induces cleavage of PS1 protein. a: hIMP1 is glycosylated in mammalian cells and is detected by immunoblot as
two major modi¢ed protein fractions (45^50 and 70^100 kDa). b: Coexpression of PS1wt holoprotein with hIMP1wt (but not with mock 1
and 2 (pcDNA4 or pcDNA6 plasmids)), in HEK293 cells induces cleavage of the PS1 holoprotein. c: Appearance of additional derivative for
CTF, but not for NTF, suggests the cleavage occurred in the carboxy-terminal part of PS1. d,e: Analysis of PS1 isoforms with 23 amino acids
deletion in N-terminus (PS1v5^27) and 23 amino acids deletion in C-terminus (PS1v445^467). d: The N-terminal PS1 NT (PS1 N-M) Abs
were unable to detect the PS1 omitting the N-terminal amino acid, whereas C-terminal PS1 CT (G1L3) Ab detected this isoform. e: In cells co-
expressing PS1 and hIMP1 the Z1-cleaved PS1v-C fragment was detected for PS1wt holoprotein, but not for PS1 lacking the C-terminal tail.
f : AD mutations in PS1 substrate did not abridge the IMP1-induced proteolysis. The comparison of PS1wt and PS1 C410Y (AD mutant) is
shown. g: Mutation analysis of the last HD of PS1 (HD X) predicted as a target for hIMP1 cleavage. Mutation G442V in a motif predicted
for cleavage abolished the endoproteolysis, whereas the more distantly located mutations did not a¡ect the cleavage. h: Mapping of Z1-cleavage
site by comparison of Z1-cleaved PS1v-C fragment with PS1 carrying systematic deletions in C-terminus. Protein lysates from cells coexpressing
(1) PS1wt and hIMP1wt and (2) series of PS1 truncated isoforms were run in 10% Tris^glycine SDS^polyacrylamide gel. The comparison of
the sizes of the proteolytic fragment and the truncated isoforms was performed in replications. The cleavage site was predicted in HD X be-
tween 432 and 445 nearby 441 residue (comparison with series of other C-terminal deletions is not shown). Asterisks indicate non-speci¢c
band.
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in mammalian cells and does not undergo the intense cleavage
(Fig. 2a) described for ‘PSase’-regulated processing of PSs
[16,21]. However, the less e⁄cient proteolytic processing of
hIMP1 in some cells may not be excluded. We made the
mutations in the evolutionary invariant residues in each of
the most conserved domains of hIMP1 (Fig. 1) and searched
for potential proteolytic substrates for the hIMP1.
We unexpectedly found, in coexpression experiments using
live mammalian cells, that a PS1wt may be processed via the
activity of hIMP1wt (Fig. 2). The Western immunoblot with
Ab against N-terminus of PS1 demonstrated production of an
additional PS1 fragment (PS1wt-vC) in HEK293 cells coex-
pressing hIMP1wt and PS1wt. The molecular mass of this
product is slightly lower than of PS1 holoprotein, suggesting
that the cleavage (designated as Z1) may occur near the end of
the PS1 protein. We found that neither the PS1 holoprotein
nor PS1wt-vC was phosphorylated or glycosylated (not
shown) and, apparently, the PS1wt-vC fragment was a pro-
teolytic product of the PS1 holoprotein (Fig. 2b,c,e).
We next addressed the question whether naturally occurring
AD mutations in PS1 may a¡ect the cleavage of PS1 regulated
by hIMP1wt. We found that hIMP1 induces cleavage of the
PS1 AD mutant PS1 holoprotein (C410Y) and produces a
proteolytic derivative similar to that found for PS1wt (Fig.
2f). These data demonstrate that the AD mutations do not
abridge PS1 holoprotein as a substrate for the hIMP1-medi-
ated cleavage. The PS1 cleavage was consistently detected by
direct immunoblot analysis of PS1 in cell lysates or membrane
fractions in multiple replicate experiments using cells transi-
ently coexpressing PS1 and hIMP1.
To assess further what part (C- or N-terminal) of PS1 is a
substrate for this cleavage we employed a variety of Abs to C-
terminal and N-terminal epitopes of PS1. Both the N-terminal
PS1 N-M and the 9N14 Abs used in this study are unable to
detect PS1 with small deletions in N-terminus (Fig. 2d). Con-
sequently, these Abs would not detect the proteolytic deriva-
tive if cleavage occurred in the N-terminus. We reasoned,
therefore, that the detectable PS1-vC proteolytic fragment
was likely generated by cleavage at the C-terminal part of
PS1. This prediction was con¢rmed further by the observation
that the PS1-vC derivative was not found for the PS1 isoform
(PS1 445 tr) omitting small portion of C-terminus (Fig. 2e).
Furthermore, no additional bands for processed 28^30 kDa
PS1 N-terminal fragment (NTF) were found, but an extra
fragment was observed for 18^20 kDa PS1 CTF (Fig. 2b).
These data provided evidence that Z1-cleavage occurs in the
C-terminal part of the PS1 holoprotein. It remains to be de-
termined whether hIMP1 may promote Z1-cleavage of the
processed PS1 CTF or if this Z1-cleavage always preludes
‘PSase’ processing of the PS1 holoprotein between domains
VI and VIII (Fig. 1b).
To determine more precisely the location of the cleavage
site, we employed a series of PS1 cDNA constructs encoding
PS1 holoproteins with systematic stop codons or deletions in
the C-terminus with average size di¡erences of 4^9 amino acid
residues. The analysis with PS1 isoforms harboring stop co-
dons, identi¢ed to be closest to the predicted Z1-cleavage site,
is shown in Fig. 2h. The putative cleavage site for PS1wt was
mapped between 432 and 445 amino acids in the middle of the
last HD X of PS1 (Figs. 1b and 2h). In addition, we designed
series of constructs with mutations in or nearby the PS1 HD
X domain (Fig. 2g). We found that only one mutation,
G442V located in a small predicted SITFG region of Z1-cleav-
age, completely suppressed the endoproteolysis. The data
demonstrate that helix-breaking residues at the center of the
membrane-embedded or membrane-spanning domain X are
critical for hIMP1-mediated endoproteolysis of PS1.
The IMP proteins share multiple sites identical to PSs, in-
cluding amino acid residues mutated in AD, as well as evolu-
tionary invariant sites occurring in bacterial peptidases, which
are supposed to be essential for their catalytic activity (Fig.
1a). Therefore, we tested next whether analogous mutations
a¡ect proteolytic properties of hIMP1. We constructed series
of mutant hIMP1 isoforms and found that D219A, D265A
and P317L mutations in hIMP1 completely abolished the
hIMP1-promoted proteolysis of PS1wt. Conversely, hIMP1
with the AD mimic mutation (G264A) retains proteolytic ac-
tivity (Fig. 3). Lastly, it was of essential interest to determine
whether Q-secretase inhibitors, thought to speci¢cally target
proteolytic properties of PS1, a¡ect also hIMP1 activity. In-
deed, we found that the L-685,458 Q-secretase inhibitor of PS
e⁄ciently inhibited hIMP1-mediated Z1-cleavage. We found,
however, that another Q-secretase inhibitor, DAPT, was inef-
fective in the suppression of IMP1 proteolytic activity on
PS1wt. The (Z-LL)2-ketone, inhibitor of SPP activity [18],
showed also a high inhibitory potency for the Z1-cleavage of
Fig. 2 (Continued).
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PS1 holoprotein (Fig. 3a^d). L-685,458 is a compound con-
taining hydroxyethylene dipeptide isostere which functions as
a transition state analog inhibitor of aspartate protease. The
L-685,458 and (Z-LL)2-ketone directly bind to protease active
sites, whereas the mechanisms of interaction of the non-tran-
sition state analog DAPT inhibitor are not yet well deter-
mined (Fig. 3e) [18,22,23].
4. Discussion
Our data demonstrate that the recently identi¢ed IMP1/SPP
is a protease capable of cleaving large transmembrane precur-
sor proteins. In cultured mammalian cells, IMP1 induced the
intramembrane cleavage of structurally related PS1 holopro-
tein. To substantiate proteolytic activity of hIMP1 against
PS1 substrates, we employed here analysis of protein extracts
from live cells. Detection assay of the proteolytic fragments in
cells transiently coexpressing these proteins was more e⁄cient
than analysis in stably transfected cells, and demonstrated
completely reproducible results in multiple replicate experi-
ments. The detection of cleavage directly by immunoblot in
this assay (Section 2) required cells overexpressing both
hIMP1 and PS1 holoproteins. The endogenous PS1 holopro-
tein is rapidly processed and generally undetectable in mam-
malian cells on a constitutive level by Western blot procedures
[21,24,25]. Therefore, the role of hIMP1 in the cleavage of
endogenous PS1 remains yet to be determined. Nevertheless,
the data suggest that IMP1 possesses or induces endoprotease
activity and proposes a simple assay to monitor proteolytic
properties of IMP1 isoforms. To our knowledge, this ¢nding
Fig. 3. Inhibition of the PS1 endoproteolysis by mutations in hIMP1 and by chemical compounds. a: Mutations in evolutionary invariant as-
partates (putative catalytic sites) and proline residue (PAL motif) in hIMP1 and Q-secretase inhibitor abolished the cleavage of PS1wt holopro-
tein. The AD mimic G264A mutation in hIMP1 did not suppress the PS1 endoproteolysis. b: Analysis of CTF also revealed the proteolytic
fragment for PS1wt, but not for the aspartate or proline mutants. Two common CTF bands are detected in high resolution SDS^polyacryl-
amide gel electrophoresis (PAGE). c: Determination of compounds inhibiting the hIMP1-mediated endoproteolysis of PS1 protein. HEK293
cells coexpressing PS1 isoforms with hIMP1wt or mock were incubated with dimethyl sulfoxide (DMSO) or 75 WM DAPT, 7.5 WM L-685,458
and 38 WM (Z-LL)2-ketone, in concentrations described to be e⁄cient to inhibit intramembrane proteolysis [18,22,23]. The protein lysates were
analyzed by immunoblot. DAPT or control DMSO did not abolish the cleavage of PS1wt, but the L-685,458 and (Z-LL)2-ketone completely
inhibited the cleavage. d: Histogram showing evaluation of the Z1 proteolytic cleavage of PS1wt. The PS1 protein fragments were directly de-
tected in protein lysates from HEK293 cells by immunoblots. The proteolytic PS1v-C fragments were quantities as percent ratio to uncleaved
PS1 holoprotein. In the absence of transfected hIMP1 the PS1 cleavage is undetectable in HEK293 cells by this assay. The Q-secretase inhibitor
L-685,458 strongly inhibited the cleavage. Mean values US.E.M. in three independent experiments are shown. e: Structure of chemical com-
pounds used in the experiments.
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is the ¢rst evidence that a multipass protein may be a direct
substrate for intramembrane proteolysis. Beyond the biologi-
cal signi¢cance of this novel intramembrane-type proteolysis,
these data imply that polytopic proteases may not only have
enzymatic activity, but be themselves substrates for other in-
tramembrane proteases.
We previously identi¢ed and named these PS-related pro-
teins as IMPAS (IMP) and classi¢ed them by hierarchical
homology to the most conserved member IMP1: IMP1 (chr
20), IMP2 (chr 12), IMP3 (chr 15), IMP4 (chr 19), IMP5 (chr
17) [15,16]. Other terms have also been proposed for the same
proteins (PSH/SPPL) and, especially, SPP (identical to IMP1)
to designate its speci¢c SPP activity [17,18]. It may be pointed
out that the signal peptide protease and SPP terms have also
been in use for other types of unrelated proteases, cleaving
bacterial or chloroplast proteins [26]. The signal peptides are
likely also not exclusive substrates for SPP/IMP1 or other bi-
aspartic intramembrane proteases. For example, the bacterial
Eep, resembling human intramembrane metalloprotease S2P,
regulates cleavage of signal peptides in bacteria [1]. The SPP-
type cleavage requires prior endoproteolysis by signal pepti-
dase (SP) as described for RIP two-step proteolysis [1,18]. The
data reported here demonstrated putative proteolytic activity
of the IMP1/SPP beyond the cleavage of signal peptides. The
primary extracytosolic cleavage is not expected to be a pre-
requisite for this type of intramembrane proteolysis. It was
assumed that the initial cleavage of the extracytosolic frag-
ment of both type I and type II proteins to short segment
(6 30 amino acids) is a common prerequisite for the second-
ary cleavage by intramembrane proteolysis [1]. Based on the
data reported here, we postulate that the holoprotein harbor-
ing HD, adjusted to short C-terminal tail, may undergo intra-
membrane cleavage without extracytosolic proteolysis (the
process which may be termed as direct intramembrane pro-
teolysis (DIP)). This proteolytic cleavage activity may result in
production of C-terminal truncated PS1 isoform lacking s 25
C-terminal residues. Other putative substrates for IMP1/SPP
with similar protein structure may be anticipated.
Interestingly, the last hydrophobic C-terminal PS1 domain
HD X cleaved by hIMP1 strictly resembles domain HD VII of
PS1 holoprotein, which is constitutively cleaved by a not yet
precisely elucidated ‘PSase’. The similarities between these
domains include hydrophobicity and location predictions at
the end of mature protein derivates (NTF or CTF), common
conserved motif (PAL) and the location of helix-breaking res-
idues in the middle of the domains (Fig. 1). It might be of
interest to investigate further whether members of IMPAS
proteins contribute also to ‘PSase’ cleavage. The HD X may
be either a membrane-inserted, but not -spanning, or lipid
bilayer-spanning domain, according to di¡erent models (Fig.
1) [27,28]. The topology, and thereby orientation, of the PS1
C-terminus to lumen or cytosolic space may possibly be dy-
namically regulated [27] and a¡ect the e⁄ciency of cleavage
by hIMP1. Mutation analysis and testing with chemical com-
pounds demonstrated here and elsewhere [8,18] imply that
IMP/SPP, as its distant PS homologs, are likely bi-aspartic
proteases with similar catalytic but di¡erential pharmacolog-
ical potency.
Finally, it was shown by systematic deletion analysis that
truncation of only a few last C-terminal residues in PS1 AD
mutant isoforms abolishes the overproduction of AL42 [20].
Therefore, the role of the intramembrane proteolysis in regu-
lation of PSs and AD modulation have to be investigated. It
would be important to determine further whether IMP/PSH/
SPP proteins, similarly to PS1, regulate neurodegeneration
processes or normal development in vivo. Because of the
abundant presentation of the IMP-like homologs in all major
taxons, including single cellular organisms, the identi¢cation
of the evolutionary conserved functional pathway of these
new putative intramembrane proteases is of great interest.
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